Roxadustat China Phase 3 Trial for Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine (NEJM)

    NEXT STORY
    Roche affiche une très bonne performance au premier semestre 2019 – prévisions pour l’année révisées à la hausse
    PREV STORY
    The New England Journal of Medicine (NEJM) Publishes Roxadustat China Phase 3 Results for the Treatment of Anemia in Chronic Kidney Disease Patients Receiving Dialysis
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs

    SAN DIEGO, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a San Diego-based ...

    author_avatar
    NASDAQ Market News

    VIFOR PHARMA GROUP REPORTS STRONG H1 2018 RESULTS, RAISES FULL-YEAR GUIDANCE

    Strong financial performance in H1 2018 Three medium-term strategic growth drivers fully on track ...

    author_avatar
    NASDAQ Market News

    Applied Therapeutics Appoints Adam Hansard as Chief Commercial Officer

    author_avatar
    NASDAQ Market News